The broad biological impact of liver disease-related increase in ADAM17 expression and activity could therefore make inhibition of ADAM17 activity a potential novel target for treating both cholestasis associated liver injury and sickness behavior development. This evidence concerns the gene ADAM17 and liver disorder.